CXCL16 and pachyonychia congenita: Collectively, these results indicate that CXCL16/CXCR6 signaling, which is activated when ZEB1 is knocked down, mediated recruitment and activation of CD8+ T cells, rendering PC tumors highly vulnerable to chemoimmunotherapy and T cell therapy.